<DOC>
	<DOCNO>NCT02315001</DOCNO>
	<brief_summary>A single-centre double-blind placebo-controlled crossover randomise control trial determine physiological basis glucagon-like peptide-1 receptor activation exercise haemodynamics , manifest specific electrophysiological parameter measure serial exercise stress testing , patient reversible myocardial ischaemia obstructive coronary artery disease confirm baseline exercise test coronary angiography respectively .</brief_summary>
	<brief_title>Liraglutide Improve corONary Haemodynamics During Exercise streSS</brief_title>
	<detailed_description>Glucagon-like peptide-1 ( GLP-1 ) , endogenous incretin hormone , secrete gut response enteral nutrition responsible primarily normal glucose homeostasis . There defective incretin effect Type II diabetes mellitus meal-stimulated GLP-1 secretion markedly impair . However , continuous infusion exogenous GLP-1 result near normal insulin response glucose load , suggest preservation insulinotropic activity . Liraglutide , synthetic analogue share 97 % structural homology native GLP-1 , guideline-mandated antidiabetic therapy give once-daily subcutaneous injection . Evidence emerge animal latterly human study suggest GLP-1 , independent effect glycemic control weight loss , may protect heart myocardial ischaemia/reperfusion injury could potentially modulate metabolic haemodynamic outcome patient coronary artery disease leave ventricular systolic dysfunction . The investigator aim determine whether chronic GLP-1 receptor occupancy effect exercise haemodynamics patient know chronic stable angina , evidence reversible ischaemia exercise stress test angiographic evidence obstructive coronary artery disease . Each study participant randomise enter either GLP-1 treatment arm volume-matched saline placebo arm . Those randomise GLP-1 week 's run-in phase 0.6 mg Liraglutide follow week 's course 1.2 mg Liraglutide . At end Week 2 , patient treatment arm first exercise tolerance test ( ETT ) . They up-titrated high dose 1.8 mg Liraglutide another week perform Week 3 ETT . Patients placebo arm match volume saline injection first two week Week 2 ETT another week saline injection Week 3 ETT . At end Week 3 patient crossover GLP-1 treatment arm cross placebo arm vice versa . By incorporate run-in phase follow step-wise increase Liraglutide therapy 3-week period investigator aim minimise occurrence adverse reaction also hope observe dose-response effect exercise haemodynamics . The crossover design allow study participant effectively act control .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Men woman age 1880 2 . Patients recent abnormal exercise tolerance test demonstrate &gt; 0.1 mV planar downsloping STsegment depression . 3 . Patients know coronary artery disease angiographic evidence &gt; 70 % stenosis main epicardial artery , without coronary stenosis elsewhere . 4 . Patients must able walk confidently treadmill . 5 . Patients must normal rest electrocardiogram ( ECG ) sinus rhythm without bundle branch aberration conduction disturbance . 6 . Patients must normal leave ventricular function . 1 . An abnormal resting ECG include atrial fibrillation , bundle branch aberration conduction disturbance . 2 . Preexisting leave ventricular systolic dysfunction . 3 . Preexisting ischaemic nonischaemic cardiomyopathy . 4 . Preexisting valvular heart disease . 5 . Inability safely negotiate exercise treadmill . 6 . Type I diabetes mellitus . 7 . Type II diabetes mellitus take oral subcutaneous anti diabetic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Liraglutide</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Ischaemic heart disease</keyword>
	<keyword>Coronary heart disease</keyword>
	<keyword>Chronic stable angina</keyword>
</DOC>